Research
Hormonal
Tirzepatide treatment significantly decreased serum glucose levels after fasting and improved glucose tolerance compared with semaglutide treatment.
Tirzepatide may offer better glycemic control than semaglutide in obese individuals.
StrongSupportsmedium confidence
Further, tirzepatide treatment improved glucose tolerance compared with semaglutide treatment.
Why this rating
Supported by comparative analysis of treatment effects.
Source
Dual GIPR and GLP‐1R agonist tirzepatide inhibits aeroallergen‐induced allergic airway inflammation in mouse model of obese asthma
Shinji Toki et al. · Clinical & Experimental Allergy · 2022
DOI 10.1111/cea.14252
otherCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →